Minimalistic Initial Therapy Options For Low Risk Papillary Thyroid Cancer

Similar documents
Dynamic Risk Stratification:

Risk Adapted Follow-Up

Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD

WTC 2013 Panel Discussion: Minimal disease

Gerard M. Doherty, MD

Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer

2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines

How Will (Should) the Latest Guidelines Affect the Endocrinologist s Management of Thyroid Cancer? AACE 2017

Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer

New York, the nation s thyroid gland. Christopher Morley ( ), "Shore Leave"

Dilemmas in Cytopathology and Histopathology

Thyroid Surgery: Lobectomy, total thyroidectomy, LN biopsies or only watchful waiting?

Management of Recurrent Thyroid Cancer

Persistent & Recurrent Differentiated Thyroid Cancer

Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology

How good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status

Differentiated Thyroid Carcinoma

AACE Thyroid Cancer Tumor board 25 years of the Endocrine and Surgery collaboration

(Not so) New Guidelines for Management of Thyroid Nodules and Differentiated Thyroid Cancer Minnesota/Midwest Chapter of AACE

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology

Current Issues in Thyroid Cancer Surgery in 2017

Key Topics in Thyroid Cancer Worldwide epidemic What Should the Endocrinologist and Surgeon do?

YCN Thyroid NSSG. *** VALID ON DATE OF PRINTING ONLY - all guidelines available at *** page 1 of 8 version number: 1.

Thyroid nodules. Most thyroid nodules are benign

Thyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary

NIFTP: Histopathology of a Cytological Monkey Wrench. B. Wehrli

What s an NIFTP? Keeping Up To Date in Thyroid 2018

Megan R. Haymart, MD 83 rd Annual Meeting of the ATA October 16, 2013

- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer

AGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA DIAGNOSIS AND PROGNOSIS

40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016

Ini7al Staging of Follicular Cell-derived Thyroid Cancers: the ATA 2015 IRS and AJCC 8th Ed. Cancer Staging Systems

Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney

Thyroid nodules 3/22/2011. Most thyroid nodules are benign. Thyroid nodules: differential diagnosis

4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.

5/18/2013. Most thyroid nodules are benign. Thyroid nodules: new techniques in evaluation

Disclosures Nodal Management in Differentiated Thyroid Carcinoma

An Alphabet Soup of Thyroid Neoplasms

Initial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits?

Managing Thyroid Microcarcinomas

PEDIATRIC Ariel Katz MD

Management of Thyroid Nodules

42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50%

Clinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease

Preoperative Evaluation

Surgical Treatment for Papillary Thyroid Carcinoma in Japan: Differences from Other Countries

Differentiated Thyroid Cancer: Initial Management

Pathology of the Thyroid

I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER

CAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.

2015 ATA Thyroid Nodule and DTC Guidelines: Perspectives from the Chair What were you thinking????

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.

3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women

THYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine

Prophylactic Central Compartment Neck Dissection(CCND) for Papillary Thyroid Cancer: Con

ELIZABETH CEDARS DR. KOREY HOOD Available September 29

FACULTY OF MEDICINE Active surveillance as the initial treatment of papillary thyroid microcarcinoma: a 10-years multicentric prospective study

A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study

Papillary Thyroid Microcarcinoma Presenting as Horner s Syndrome: A Novel Clinical Presentation

Review Article Management of thyroid carcinoma Alauddin M, Joarder AH

Clinical outcomes after delayed thyroid surgery in patients with. papillary thyroid microcarcinoma

Pediatric Thyroid Cancer Lung Metastases. Liora Lazar MD

POORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT?

Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer

Thyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES

The Frozen Section: Diagnostic Challenges and Pitfalls

Introduction. Materials and methods Y-N XU 1,2, J-D WANG 1,2

Well Differen*ated Thyroid Microcarcinoma. Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel School of Medicine at Dartmouth

Carcinoma tiroideo differenziato: gestione della persistenza biochimica di malattia

Oncological outcomes for patients with well differentiated thyroid cancer Nixon, I.J.

1. Protocol Summary Summary of Trial Design. IoN

10/24/2008. Surgery for Well-differentiated Thyroid Carcinoma- The Primary

Changing trends in the management of well-differentiated thyroid carcinoma in Korea

THE FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA AND NIFTP

Management of Thyroid Nodules. February 2 nd, 2018 Sarah Hopkins

Towards a selective use of postoperative radioiodine in thyroid cancer patients

Markers in Thyroid Nodule Evaluation. Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center

PRACTICE GUIDELINES: Thyroid Nodules and Cancer 2017 ESEO Alexandria

The use of Radioactive Iodine (RAI) for Differentiated Thyroid Cancer

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules

Surgical Management of Thyroid Disease. Tom Shi Connally, MD, FACS

Review Article Thyroidectomy and Lymph Node Dissection in Papillary Thyroid Carcinoma

Endocrine Surgery When to Refer and What We Do

Follicular Derived Thyroid Tumors

Thyroid Ultrasound for the Endocrine Surgeon: A Valuable Clinical Tool that Enhances Diagnostic and Therapeutic Outcomes

Thyroid US. Background: Thyroid/Neck US. Use of Office Ultrasound in the Thyroid Surgery Practice

Differentiated Thyroid Cancer: Reclassification of the Risk of Recurrence Based on the Response to Initial Treatment

Long Term Follow-Up for Differentiated Thyroid Cancer: The Mayo Experience

Oh, I get it, the TSH goes up and down

04/09/2018. Follicular Thyroid Tumors Updates in Classification & Practical Tips. Dissecting Indeterminants. In pursuit of the low grade malignancy

Volume 2 Issue ISSN

Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid

Fuqiang Li, Yijun Wu, Liang Chen, Liang Hu, Xiaosun Liu. Original Article

Evaluation and Management of Thyroid Nodules. Overview of Thyroid Nodules and Their Management. Thyroid Nodule detection: U/S versus Exam

Mandana Moosavi 1 and Stuart Kreisman Background

Evaluation of thyroid isthmusectomy as a potential treatment for papillary thyroid carcinoma limited to the isthmus: A clinical study of 73 patients

Management guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007

Transcription:

Minimalistic Initial Therapy Options For Low Risk Papillary Thyroid Cancer An emphasis on proper patient selection R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Medical College of Cornell University

Minimalistic Treatment Options Active Surveillance (0bservation) Thyroid Lobectomy Not for every low risk thyroid cancer Not for every patient Not for every clinician

Observational Management Approach to Papillary Microcarcinoma 2,153 Low Risk Papillary Microcarcinoma Patients Dr Akira Miyauchi Kuma Clinic Japan Active Surveillance 1,179 (55%) Immediate Surgery 974 (45%) Median Follow-up 4 yrs (range 1-10 yrs) Continued Observation 1,085 (92%) Surgery, Stable Disease 61 (5.2%) Increase Size Primary Tumor 27 (2.3%) Novel LN Metastasis 6 (0.5%) Salvage therapy is very effective Oda et al, Thyroid 2016; 26(1): 150-155 Ito et al. World J Surg. 2010;34(1):28-35. Sugitani et al. World J Surg. 2010;34(6):1222-1231. Ito et al. Thyroid. 2013.

Active Surveillance of Low Risk Papillary Thyroid Cancer 291 MSKCC patients < 1.5 cm PTC/Suspicious PTC Median 2 yr follow up, Median age 51 yrs (20-86) Diameter increase of 3mm Volume increase of 50% Cumulative incidence 2.5% Cumulative incidence 12.1% 11.5% 24.8% Time (months) Time (months) Time 0 12 24 36 48 60 n 291 243 145 78 39 18 Time 0 12 24 36 48 60 n 291 236 138 71 34 15 Tuttle et al, JAMA Otolaryngology Head & Neck Surgery, 2017

192 PMC Patients Followed for 1 year (Median 2.5 yrs) Decrease volume Stable Volume Increase 3mm & Increase volume Increase volume without 3 mm increase Novel LN metastasis (33/192) (132/192) (4/192) (27/192) (1/192) 17% 69% 2% 14% 0.5% Asan Medical Center, Seoul, Korea JCEM June 2017

Active Surveillance of Low Risk PTC Outcomes are similar Japan, USA and Korea 10-15% increase volume over several years Young patients more likely to increase volume 1-2% have LN mets identified Salvage therapy very effective

Implementing Active Surveillance in the US Requires concurrent evaluation of three inter-related domains Tumor/US Inappropriate Ideal Medical Team Patient Appropriate A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. JP Brito, Y Ito, A Miyauchi, RM Tuttle. Thyroid 2015

Proper Patient Selection Tumor/US Intrathyroidal PTC Bethesda VI Bethesda V with highly suspicious US (Highly suspicious US without FNA) Cytology interpretation and US examination at MSKCC Primary tumor up to 1.5 cm Acceptable Features Background thyroid abnormalities (Hashimoto s, MNG) BRAF V600E mutation (genetic testing not required) Without Documented increase in size LN metastases Extrathyroidal extension Subcapsular location adjacent to trachea/rln JP Brito, Y Ito, A Miyauchi, RM Tuttle. Thyroid 2015

Relationship of Nodule to Thyroid Capsule Ideal: normal thyroid tissue surrounding the PMC

Relationship of Nodule to Thyroid Capsule Inappropriate 67 yr old female, right anterior superior pole, 8x7x9mm, definite anterior extrathyroidal extension, confirmed by histology (7mm TCV PTC, minor ETE)

Course of the Recurrent Laryngeal Nerves Relative to the Intact Thyroid Gland Surgery of the Thyroid And Parathyroid Glands, Randolph G, editor

Biopsy Proven PTC In Worrisome Location Posterior Right Lobe Nodule (6x8x6mm)

Biopsy Proven PTC In Worrisome Location Left Mid Pole Nodule (13x10x11mm) Ara Chalian, U Penn: 3-4 mm section of RLN involved

Implementing Active Surveillance in the US Requires concurrent evaluation of three inter-related domains Tumor/US Multidisciplinary Management Team Shared Treatment Philosophy Quality Ultrasonography Prospective Data Collection Tracking System Medical Team Patient Motivated Compliant Supportive Family/Clinicians Differences in Patient Decision Making JP Brito, Y Ito, A Miyauchi, RM Tuttle. Thyroid 2015

How do patients perceive initial treatment options? SURGERY ACTIVE SURVEILLANCE Slide from Elizabeth Grubbs, MD Anderson BOTH D Agostino et al. Psychooncology, 27:61-68, 2018.

How do patients perceive initial treatment options? SURGERY ACTIVE SURVEILLANCE Sense of urgency Perception as potentially life threatening disease Fear of disease progression & uncertainty with active surveillance Surgery as a means of control and potential cure Slide from Elizabeth Grubbs, MD Anderson BOTH D Agostino et al. Psychooncology, 27:61-68, 2018.

How do patients perceive initial treatment options? SURGERY ACTIVE SURVEILLANCE Sense of urgency Perception as potentially life threatening disease Fear of disease progression & uncertainty with active surveillance Surgery as a means of control and potential cure View as a common, indolent, low risk disease Concerns about adjusting to life without a thyroid/ reliance on hormone replacement Openness to reconsidering surgery over the long run Slide from Elizabeth Grubbs, MD Anderson BOTH D Agostino et al. Psychooncology, 27:61-68, 2018.

How do patients perceive initial treatment options? SURGERY ACTIVE SURVEILLANCE Sense of urgency Perception as potentially life threatening disease Fear of disease progression & uncertainty with active surveillance Surgery as a means of control and potential cure Deep level of trust & confidence in physician & cancer center Use of physician & internet as 1 sources treatment related info View as a common, indolent, low risk disease Concerns about adjusting to life without a thyroid/ reliance on hormone replacement Openness to reconsidering surgery over the long run Slide from Elizabeth Grubbs, MD Anderson BOTH

Weighing the Risks and Benefits of Treatment Medical Decision Making Maximalists or Minimalists Believers Or Doubters Technology Orientation Or Naturalistic Orientation

Weighing the Risks and Benefits of Treatment Medical Decision Making Maximalists Cancer Blood pressure Cholesterol Glucose BMI Availability Bias Minimalists Cancer Blood pressure Cholesterol Glucose BMI be ahead of the curve why wait more is better Believers Technology Orientation less is more unintended consequences outweigh potential benefits Doubters Naturalistic Orientation Development of the Medical Maximizer-Minimizer Scale. Scherer et al, Health Psychology, 2016

Implementing Active Surveillance in the US Applicable to primary tumor, LN mets, and distant metastases Tumor/US Ideal Tumor Volume Follow-up Strategy Patient Appropriate Rate of Change (Doubling Time) Intervention Indications Medical Team Inappropriate Tumor Location Proper Selection Active Surveillance Management Decisions

Observational Management Strategy Serial US evaluations of the thyroid and neck Q 6 months for 2 years Then less frequently TSH suppression is not recommended Goal TSH 0.5-3 miu/l Thyroid function tests Yearly Indications for surgical intervention Increase in tumor volume (doubling time) Identification of metastatic disease Development of extrathyroidal extension Other worrisome ultrasonographic changes Patient preference JP Brito, Y Ito, A Miyauchi, RM Tuttle. Thyroid 2015

Selecting Patients for Lobectomy Intra-operative Findings Post-operative Path Report Tumor/US Medical Team Ideal Inappropriate Patient Appropriate R. Michael Tuttle, Ling Zhang and Ashok Shaha, Expert Review of Endo & Metab, 2018.

Selecting Patients for Lobectomy Intra-operative Findings Post-operative Path Report Tumor/US Medical Team Immediate Completion 6-20% Delayed Completion 5-10% Ideal Inappropriate Patient Effective Salvage Therapy Appropriate Nixon Surgery 2012, Vaisman Clinical Endo (Oxf) 2011, Vaisman J Thyroid Res 2013, Kluijfhout Surgery 2017, Calcatera Endo Practice 2017

A Clinical Framework for Decision Making with Regard to Extent of Initial Surgery Pre-operative/Intra-operative Decision Making Tumor/Imaging characteristics Ideal Solitary nodule Intrathyroidal 1 cm Clinical N0 neck Patient characteristics Minimalist mentality Motivated patient Willingness to accept possibility of small volume disease in contralateral lobe Desire to preserve thyroid function Desire to minimize surgical complications Open to intra-operative decision making Medical Team Experienced MDT Experienced US Shared treatment philosophy Uses RAI very selectively for ablation/adjuvant therapy and follow up Frozen section available R. Michael Tuttle, Ling Zhang and Ashok Shaha, Expert Review of Endo & Metab, 2018.

A Clinical Framework for Decision Making with Regard to Extent of Initial Surgery Pre-operative/Intra-operative Decision Making Tumor/Imaging characteristics Appropriate 1-4 cm Benign appearing changes on US (Hashimoto s, benign nodules) Benign appearing LN s Clinical N0 Patient characteristics Minimalist/Maximalist Desire to keep normal thyroid (or avoidance of surgical complications) outweighs concern for disease in the contralateral lobe or the desire for RAI Medical Team Surgeon and endocrinologist agree on post-op management plan Unlikely to include need for RAI Comfortable that follow-up US is adequate for low risk patient R. Michael Tuttle, Ling Zhang and Ashok Shaha, Expert Review of Endo & Metab, 2018.

A Clinical Framework for Decision Making with Regard to Extent of Initial Surgery Pre-operative/Intra-operative Decision Making Tumor/Imaging characteristics Inappropriate >4 cm Extrathyroidal extension Metastatic cervical LN s Distant metastases Multifocal, macroscopic PTC High risk molecular profile Patient characteristics Maximalist mentality Patient desires total thyroidectomy and/or RAI Indications for RAI ablation/adjuvant therapy/staging Medical Team Treatment team desires RAI for scanning/therapy or optimized serum Tg for staging and follow-up R. Michael Tuttle, Ling Zhang and Ashok Shaha, Expert Review of Endo & Metab, 2018.

Post-operative Decision Making Features Ideal Intrathyroidal classical PTC FV-PTC without vascular invasion NIFT-P Minimally invasive FTC (capsular invasion only) Pathology N0/Nx Non-stimulated Tg < 5 ng/ml Appropriate Minor extrathyroidal extension Clinical N0 but pn1 LN mets Multifocality Lymphovascular invasion Minor vascular invasion 1-2 cm potentially aggressive tumors (tall cell, hobnail, columnar cell) Non-stimulated Tg 5-30 ng/ml Inappropriate Extensive vascular invasion (FTC or HCC) Gross extrathyroidal extension Clinical N1 histologically confirmed LN mets Non-stimulated Tg > 30 ng/ml R. Michael Tuttle, Ling Zhang and Ashok Shaha, Expert Review of Endo & Metab, 2018.

Proper Patient Selection for Lobectomy Ongoing dynamic risk stratification Tumor/US Patient Ideal Appropriate Intra-Op Findings Ideal Appropriate Medical Team Inappropriate Post-Op Findings Inappropriate Pre-Op Evaluation Pre-Op Classification Additional Information Post-Op Classification R. Michael Tuttle, Ling Zhang and Ashok Shaha, Expert Review of Endo & Metab, 2018.

A Practical Approach to Follow-up After Lobectomy Excellent disease specific survival Highly sensitive disease detection techniques are not necessary Tumor/Imaging characteristics TSH goal 0.5-2.5 miu/ml With or without levothyroxine Clinic visits Post-op (to review path, check TSH, Tg) Then 6-12 month follow-up Yearly for 2-3 years with exam TSH, Free T4, Tg, TgAb with each clinic visit Imaging Neck US 6-12 months, 3 yrs, and 5 yrs Then very rarely Late completion thyroidectomy Physical exam findings Neck US findings Need for RAI Sustained, serial rise in Tg over time

Minimalistic Treatment Options Active Surveillance (0bservation) Thyroid Lobectomy Not for every low risk thyroid cancer Not for every patient Not for every clinician